SEC Tracker
Get the app

Marpai MRAI

Marpai FY 2025: revenue $18.1M, down 36%; diluted EPS −$0.95

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Marpai reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$18.1M−36% from $28.2M in FY 202410-K income statement, on EDGAR
  2. Net income−$16.6MAgainst −$22.1M in FY 202410-K income statement, on EDGAR
  3. Diluted EPS−$0.95Against −$1.92 in FY 202410-K income statement, on EDGAR
  4. Cash and cash equivalents$133K−83% from $764K in FY 202410-K balance sheet, on EDGAR
  5. Cash from operations−$7.5MAgainst −$15.2M in FY 202410-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Marpai files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (8090) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. BioRestorative Therapies BRTX public float $11M, Jun 30, 2025
  2. Mangoceuticals MGRX public float $15M, Jun 30, 2025
  3. Pacific Health Care Organization PFHO public float $3M, Jun 30, 2025
  4. AnTix Holdings IMTH public float $2M, Dec 31, 2025
  5. Cryo Cell International CCEL public float $27M, May 31, 2025